We then employed genome editing to correct the dosage of the Ifnr locus in a mouse model of DS, which revealed that the Ifnr locus contributes to multiple key phenotypes in mice, with potential therapeutic implications for the management of this condition. This evidence concerns the gene IFNAR2 and Dravet syndrome.